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ABSTRACT  
Objective: The present research is aimed to enhance the dissolution rate of Efavirenz using liquisolid compact technology.  
Methods: About 16 
Results: A 2
different formulations were developed using factorial design with carriers (Neusilin and Fugicalin), binder (PVP K-30) and 
vehicle (polyethylene glycol 300) as independent variables and aerosil 200 is used as coating material. The In-vitro drug release from the LSC has 
used a dependent variable. The empirical method by Spireas and Bolton was applied to calculate the amounts of carrier and coating materials and 
obtained the improved flow characteristics and hardness by changing the proportion of carrier and coating materials. 
3
Conclusion: LSC technique confirmed the enhanced dissolution rate of Efavirenz, which in turn helps in improving bioavailability. 
 factorial design is used and developed LSC using Neusilin (LSC-N1 to LSC-N8) and Fugicalin (LSC-F1 to LSC-F8). The physicochemical 
evaluation of all formulations exhibited well within the specification limits with respect to weight variation, hardness, friability and content 
uniformity. The In-vitro drug release from these LSC was evaluated in 0.1 N HCl and the optimized formulation (LSC-N8) was compared with pure 
drug (capsule) and physical mixture (tablet). The release studies proved that the liquisolid tablets results in higher release profile than pure drug 
and physical mixture due to increase in surface and wetting properties of the drug. 
Keywords: Liquisolid compacts, Efavirenz, Neusilin, Fujicalin, Factorial design. 
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INTRODUCTION 
The active ingredient in a solid dosage form must undergo 
dissolution before it is available for absorption from the 
gastrointestinal tract [1]. The poor dissolution rate of the water-
insoluble drug is a substantial problem confronting the 
pharmaceutical industry. The absorption rate of a poorly water-
soluble drug from the solid oral dosage form is poor due to the low 
dissolution rate of the drug. Hence, the dissolution rate is the rate 
determining step in drug absorption. 
Various methods such as crystallization by solvent change, 
preparation of inclusion complexes with β-cyclodextrins, formation 
of water-soluble salts, micellar solubilization, solid dispersion, 
lyophilization, microencapsulation, liquisolid technique and the 
inclusion of drug solutions or liquid drugs into soft gelatin capsules 
are some of the techniques that have been reported to enhance the 
dissolution characteristics of water-insoluble drugs [2]. The 
technique of liquisolid compacts is one of the most promising 
techniques. Liquisolid concept is used to enhance the solubility of 
poorly water soluble drugs at least for the first two hours (active 
absorption phase) and thereby increasing drug dissolution and 
absorption rate of drugs. 
The liquisolid technique as described by Spireas is a novel concept, 
where a liquid may be transformed into a free-flowing, readily 
compressible and apparently dry powder by simple physical 
blending with selected carrier and coating material. The liquisolid 
powder is a free flowing and a compressible powder form of liquid 
medication [3]. The term liquid medication implies liquid drug and 
solution or suspension of water insoluble solid drug carried in 
suitable non-volatile liquid vehicles. Using formulation technique, a 
liquid medication can be converted into a dry-looking, non-adherent, 
free flowing, and readily compressible powder by blending with 
selected powder excipients referred to as the carrier and coating 
materials. Various grades of cellulose, starch, lactose silica powder 
may be used as the coating (or covering) material [3]. In liquisolid 
compact, the drug is in a tablet or encapsulated dosage form, and it 
is held in a solubilized liquid state, which consequently contributes 
to increased drug wetting properties, thereby enhancing drug 
dissolution. In liquisolid formulation, the drug is in either solubilized 
or molecularly dispersed state in the liquid vehicle, which is 
absorbed into or onto the carrier and coating material respectively. 
Hence, increased surface area of the drug in powder form and 
enhanced dissolution of drug [2]. 
Spireas et al. proposed the new mathematical model to retain good 
flow behavior and compressibility to design the liquisolid 
formulation technique. This technique requires a suitable drug 
candidate, non-volatile solvent, and carrier and coating materials. 
The basic properties of powder are proposed according to Spireas et 
al. is “Flowable liquid retention potential” (value) and “compressible 
liquid retention potential” (ψ value). Flowable liquid retention 
potential is the maximum weight of liquid (solvent) that can be 
retained per unit weight of the powder (excipient) material to 
produce good flow. Compressible liquid retention potential is the 
compression force applied to produce tablets with acceptable 
strength without squeezing out any liquid during compression. 
Excipient ratio (R) is defined as carrier to coating ratio quoted as 
given by equation (1) 
R= Q/q (1) 
Where, Q = Carrier material and q = Coating material. 
Liquid load factor (Lf
L
) is defined as the weight of liquid medicament 
(W) to the weight of carrier (w). The equation is given below (2) 
f
The Ø value is for calculating excipients quantities as shown in the 
equation (3).  
 = W/Q (2) 
Lf
Where, Ø and Ø are values of carrier and coating material [4]. 
 = Ø+Ø (1/R) (3) 
Efavirenz, chemically (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-
(trifluoromethyl)-2, 4-dihydro-1H-3, 1-benzoxazin-2-one is an Anti-
HIV agent. Efavirenz is an official drug and appears as a white or 
almost white crystalline powder. It is freely soluble in methanol, 
chloroform and very slightly soluble in water and ethanol. Efavirenz 
has a melting point of 138 °C to 140 °C; log P value of 4.6 and got a 
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pKa of 12.52. The dose of efavirenz ranges between 600 mg orally 
once a day [5]. 
Objectives  
The main aim of present study was to enhance the dissolution rate 
of Efavirenz, a BCS class-II (low soluble and high permeable drug) by 
developing the liquisolid tablets using different carriers and coating 
materials with different liquid loading factors and excipient ratios.  
The objectives of the present investigation include the following:  
1. To identify best non-volatile solvent using solubility studies for 
Efavirenz. 
2. To study the effect of different carriers and coating materials on 
dissolution rates of Efavirenz liquisolid compacts.  
3. To develop various formulations of Efavirenz liquisolid compacts 
using the design of experiments. 
4. To evaluate the developed Efavirenz liquisolid compact 
formulations for pre-compression (Angle of repose, Bulk density, 
Tapped density, Carr’s index, Hausner’s ratio) and post-compression 
parameters (Weight variation, Friability, Hardness, Disintegration 
time, Drug content uniformity, In-vitro dissolution studies). 
MATERIALS AND METHODS 
Efavirenz is a gift sample (Hetero Pharmaceuticals, Hyderabad), 
Neusilin and Fujicalin are free samples (Gangwal Chemicals Pvt Ltd). 
Aerosil 200, PVP K-30, Cross caramellose sodium, Magnesium 
stearate, Lactose, Propylene glycol (PG), Glycerine, Tween 80, PEG 
400, PEG 300 are procured from S. D. Fine Chem Limited, Mumbai 
and used in the study.  
Experimental methodology  
Estimation of efavirenz 
Efavirenz estimation was made in 0.1N hydrochloric acid (pH 1.2) 
solution at λmax of 247 nm by UV spectrophotometry (UV-1700, 
Shimadzu, Japan). The calibration curve was obeyed Beer Lambert’s 
law in the concentration range of 0-40 µg/ml (R2
Characterization of efavirenz 
 = 0.997) [3]. 
The efavirenz purity was characterized by melting point, FT-IR 
studies, DSC studies and XRD studies. The micrometric properties of 
efavirenz were determined by the angle of repose, bulk density, 
tapped density, compressibility index, and Hausner’s ratio. 
Drug-excipient compatibility studies 
The excipients used in the formulation were selected from drug-
excipients compatibility studies using spectral interference and 
Fourier Transform Infrared (FTIR) Spectroscopy analysis. 
Saturation solubility studies 
The solubility studies were performed for the selection of best non-
volatile solvents. Excess of efavirenz was placed in ten ml of five 
different non-volatile solvents (propylene glycol, Tween 80, PEG 
300, PEG 400, and glycerine) and these dispersions were stirred in 
orbital shaker bath for 72 h at 25 o
Determination of the flowable liquid retention potential 
C. The saturated solutions were 
filtered after 72 h using Whattman filter paper (0.22 µm) and the 
filtrate was analyzed spectrophotometrically at 247 nm. The studies 
were conducted triplicate [6, 7]. 
In constant weight of carrier/coating material, increasing amount of 
solvent was incorporated and on each addition, the angle of slide 
was determined. The Flowable liquid retention potential (Ø-value) 
of each liquid/powder admixture was calculated using the following 
equation (4). 
Ø − 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 =  weight  of  liquid  weight  of  solid  ....... (4) 
The Ø-values were plotted against the corresponding angle of the 
slide to identify optimal flow properties. The angle of slide value of 
33o
  
 corresponding to the liquid/powder admixture is represented as 
the ideal Flowable liquid-retention potential [8]. 
Table 1: Absolute values of levels of variables employed in factorial design 
S. No. Variables Levels 
Absolute Coded -1 +1 
1 Concentration of drug in the liquid vehicle (% w/w) X 50 1 75 
2 Concentration of PVP-K30 in the formulation (% w/w) X 2 2 5 
3 Concentration of super disintegrant in the formulation (% w/w) X 2.5 3 5 
 






Drug concentration in the 
liquid vehicle (% w/w) 
Concentration of PVP-K30 in the 
formulation (% w/w) 
Concentration of cross caramellose sodium 
in the formulation (% w/w) 
1 LSC-1 -1 -1 -1 
2 LSC-2 +1 -1 -1 
3 LSC-3 -1 +1 -1 
4 LSC-4 +1 +1 -1 
5 LSC-5 -1 -1 +1 
6 LSC-6 +1 -1 +1 
7 LSC-7 -1 +1 +1 
8 LSC-8 +1 +1 +1 
 
Formulation development 
The liquisolid compacts of efavirenz were developed by using 23
The factorial design was applied at lower and higher levels using 
two different carries (Neusilin and Fugicalin) and developed eight 
formulations for each carrier. The absolute levels of variables used 
in the study are given in the table 1 and the plan of experiments with 
coded levels of variables is given in the table 2. 
 
factorial design, i.e., 3 variables and 2 levels. The variables include 
the concentration of drug in the liquid vehicle (% w/w), 
concentration of binding agent (PVP K-30) in the formulation 
(%w/w) and concentration of super disintegrant (cross caramellose 
sodium) in the formulation (%w/w).  
Neusilin and Fujicalin were selected as two different carriers and 
the above-mentioned variables, and respective levels were 
assessed individually on both the carriers employed in the study. 
Using the design of experiments, eight formulations for each of 
Neusilin (LSC-1N to LSC-8N) and Fugicalin (LSC-1F to LSC-8F) 
were developed using direct compression technique. Formulations 
LSC-N1 to LSC-N8 were formulated using neusilin as carrier and 
formulations LSC-F1 to LSC-F8 were formulated using fujicalin as 
carrier.  
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Evaluation of liquisolid system 
Flow property 
Flow property of liquisolid admixture was accessed by measuring 
the angle of repose, Carr’s index and Hausner’s ratio. Each study was 
carried out in triplicate. The angle of repose was calculated by a 
fixed height cone method. Carr’s index & Hausner’s ratio were 
determined using bulk density apparatus as reported in the 
literature [10, 11]. 
Weight variation 
Weight variation was calculated as per method described in USP. 
Twenty tablets were selected at random and their average weight was 
determined using an electronic balance. The tablets were weighed 
individually and compared with average weight. The requirements are 
met if the weights of not more than 2 of tablets differ by more than the 
percentage listed in the table 3 and no tablets differ in weight by more 
than double that percentage [12, 13]. 
 
Table 3: Acceptance criteria for weight variation [14] 
Average weight of tablet (mg) %±deviation allowed 
130 or less 10 
More than 130 & less than 324 7.5 
324 and above 5 
 
Tablet thickness 
Thickness and diameter of formulation trials were measured using a 
digital hardness tester. 10 tablets of each trial formulation were 
taken and measured individually at frequent intervals [15]. 
Hardness 
The hardness of the liquisolid tablets was evaluated using a 
Monsanto hardness tester. The tablet to be tested was placed 
between the spindle and the anvil. The desired pressure needed to 
hold the tablet in position was applied by moving the screw knob in 
a clockwise direction. The scale was moved so that the indicator was 
fixed at zero. The pressure was applied until tablet breaks. The 
reading was noted, indicating the pressure that was needed to break 
the tablet. The mean hardness of each batch was determined and 
expressed in kg/cm2 
Disintegration test was carried out using USP tablet disintegration 
test apparatus (TGR56, Electro lab, India) using of 0.1N hydrochloric 
acid at room temperature (37±2 ⁰C). Disintegration apparatus with a 
basket rack assembly containing six open-ended tubes and 10-mesh 
screen on the bottom was used. A tablet was placed in each tube of 
the basket and the time for complete disintegration of the six tablets 




Ten tablets from each formulation were powdered. The powdered 
sample equivalent to 6 mg of drug was transferred to a 100 ml 
volumetric flask containing 5 ml of 0.1N hydrochloric acid solution. 
The contents were shaken up to 30 min and made up to mark with 
HCl. The solution was further diluted with 0.1N Hydrochloric acid 
solution if required. The drug content was determined by measuring 
the absorbance at 247 nm [18, 19]. 
In-vitro drug releases study 
In vitro drug release of the samples was carried out using USP-type 
II dissolution apparatus (paddle type). The temperature of the 
medium was maintained at 37±0.5 °C. The apparatus was allowed to 
run for 50 RPM. Aliquots of samples were withdrawn at various 
intervals. The samples were filtered through Whatman filter. Fresh 
dissolution medium (0.1N HCl solution) was replaced every time 
with the same quantity of the sample. Collected samples were 
analyzed at λmax
RESULTS AND DISCUSSION 
Characterization of efavirenz  
Melting point 
The melting point of efavirenz was determined by capillary tube 
method and it was found to be 138 °C. This value is same as that of 
the literature citation 138-140 °C (B. P 2008). 
FT-IR spectrum of pure drug 
The FT-IR spectrum for the pure drug was recorded and the 
characteristic bands are observed in the graph (fig. 3). A perusal to 
the FT-IR spectrum, it was confirmed the presence of all 
characteristic bands for the efavirenz [22]. 
Differential scanning calorimetry 
 of 247 nm. The percentage cumulative drug release 
(% CDR) was calculated [20, 21]. 
The DSC spectrum for the pure drug was recorded in the fig. 1. A 
perusal to the DSC of the drug, the peak onset was found to be 
138 o
 
C. This value is matching with the melting point obtained 
from open capillaries. Thus indicates the purity and 
confirmation of efavirenz [13]. 
 
Fig. 1: DSC thermogram of efavirenz 
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XRD of pure drug 
The purity and crystallinity of efavirenz was identified using XRD 
studies. The XRD graph of efavirenz was recorded in the fig. 2. The 
XRD studies confirm the crystalline nature of the drug. A perusal to 
the fig. 2, characteristic peaks of the drug were present at 20.20° and 
21.35°, which confirmed the crystalline nature of drug. 
 
 
Fig. 2: XRD graph of efavirenz 
 
Flow properties 
The flow properties of the pure drug were determined. It is 
observed that angle of repose; compressibility index and 
Hausner’s ratio were indicating good flow properties of the pure 
drug (efavirenz). Thus, the drug is suitable for direct 
compression. 
Drug–excipient compatibility studies 
Spectral interference analysis 
The absorbances of the solutions containing drug (10 μg/ml) and for 
a drug with the excipient mixture in 0.1 N HCl solutions were 
measured at 247 nm to determine the influence of excipients on 
drug substance (table 4). 
 
Table 4: Data obtained in the spectral interference analysis 
S. No. Sample Absorbance 
1 Drug solution without additive 0.481 
2 Drug solution with Aerosil 200 0.485 
3 Drug solution with Fujicalin 0.481 
4 Drug solution with Neusilin 0.501 
5 Drug solution with PVP K-30 0.499 
6 Drug solution with PEG 300 0.505 
 
The absorbances of the solutions (drug and additive) were almost 
closer to the absorbance of the drug solution. Thus, the analysis 
revealed that drug has no interference with the excipients used in 
the formulation. 
FT-IR studies 
The FT-IR studies were carried out to identify the compatibility of 
the excipients with the drug used in the formulation. The IR spectra 
obtained for the pure drug and for various mixtures 
(drug+excipient) are given in the fig. 3. From the fig. 3 it was found 
that, there was no significant change in the band peaks of drug-
excipient mixtures with respect to a pure drug, giving prima-facie 
evidence that there is no incompatibility of excipients with the drug. 
Saturation solubility study 
The solubility studies for efavirenz in different solvents showed a 
varied solubility as shown in the fig. 4. The maximum solubility of 
the drug was observed in PEG 300 (74.87 mg/ml) among the various 
solvents used in the study. Hence, PEG 300 was selected as a non-
solvent in the formulation of liquisolid compacts of efavirenz. 
Flowable liquid retention potential (Φ–value) 
This test is performed at 3 different ratios of carrier and coating 
material (i.e., R at 15, 20, and 25). 
 
 
Fig. 3: Overlay of FT-IR spectrum of efavirenz and mixture of 




Evaluation of liquisolid tablets 
 factorial designs, eight formulations for each of Neusilin 
and Fujicalin were developed as per the design of experiments given 
in table II. The liquisolid compacts were prepared using direct 
compression technique. The prepared tablets were subjected to various 
evaluation tests as mentioned in the methods and materials section. 
Flow properties 
Bulk density 
 It is the ratio of given mass of powder and its bulk volume determined 
by measuring the volume of known mass powder sample that has been 
passed through the screen into graduating cylinder. 
 
 
Fig. 4: Solubility studies of efavirenz in different solvents 
 
Bulk density was determined according to USP method I. The 
powder sample under test was screened through sieve no 18 and an 
appropriate amount of pure drug and the formulation blend were 
accurately weighed and filled in a 100 mL graduated cylinder and 
the powder were leveled and the unsettled volume (Vo) was noted. 
Bulk density (Db
D
) was calculated in g/ml by the formula:  
b = M/Vo 
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Where, M = mass of powder taken  
Vo
Limits: It has been stated that the bulk density values having less 
than 1.2 g/cm
 = unsettled apparent volume  
3 indicates good packing and values greater than 1.5 
g/cm3
Table 5: Flowable liquid load factor (ϕLf) for various R values 
 indicates poor packing. 
R 1/R Flowable liquid load factor(ϕLf) 
Neusilin Fujicalin 
25 0.04 0.791 0.510 
20 0.05 0.880 0.612 
15 0.06 1.020 0.751 
The ϕ values obtained for 3 different ratios are given in the table 5. The ratio R=20 is selected for the formulation of efavirenz liquisolid compacts. 
Further, the compressible liquid retention potential for R=20 is determined and obtained as 0.880 (Neusilin: Aerosil 200) and 0.612 (fujicalin: 
aerosil 200) admixtures. 
 
Tapped density 
After carrying out the procedure as given in the measurement of 
bulk density, the cylinder containing the sample was tapped using a 
mechanically tapped density tester (Electro lab). The cylinder was 
tapped until no change in volume and then tapped volume Vt was 
measured to the nearest graduated unit. The tapped density was 
calculated, in grams per mL, using the formula:  
Dt = M/Vt 
Where, M = weight of sample powder  
Vt
Carr's compressibility index, i.e., % compressibility indicates the 
flow property and packing ability of the tablet. It is determined by 
measuring both the bulk and tapped density of a powder. When the 
% compressibility ranges from 5 to16, the materials have acceptable 
flow property and packing ability. Compressibility Index was 
calculated using following equation:  
= final tapped volume  
Compressibility index (% Compressibility) 
CI (%) = (Dt-Db)/Dt
Where, D
] x 100 
t
D
 = Tapped density  
b
Hausner's ratio 
 = Bulk density  
The Hausner's ratio indicates the flowability and packing ability of 
the tablet. When the Hauser's ratio is close to 1, materials have 
acceptable flow and packing ability. Hausner's ratio was calculated 
using the formula:  





 = Tapped density  
b
 
 = Bulk density  
Table 6: Correlation of compressibility index and Hausner’s ratio with flow properties 
Compressibility Index Flow character Hausner’s ratio 
1–10 Excellent 1.00–1.11 
11–15 Good 1.12–1.18 
16–20 Fair 1.19–1.25 
21–25 Passable 1.26–1.34 
26–31 Poor 1.35–1.45 
32–37 Very poor 1.46–1.59 
≥ 38 Very, very poor ≥ 1.60 
The bulk density and tapped bulk density for all the formulations were conducted and the data were used to determine Carr’s index and Hausner’s 
ratio. The percentage compressibility for all the formulation blends of LSC-N1 to LSC-N8 and LSC-F1 to LSC-F8 lies in the range of 10.23 to 14.67 and 
10.58 to 18.25 respectively. The Hausner’s ratio for all the formulation blends of LSC-N1 to LSC-N8 and LSC-F1 to LSC-F8 lies within the range of 
1.11 to 1.17 and 1.13 to 1.22 respectively, indicated good flow properties of the blend. Further, there flow properties were confirmed by angle of 
repose for all formulation blends. 
 
Weight variation test 
Weight variation was calculated as per method described in USP. 
Twenty tablets were selected at random and their average weight 
was determined using an electronic balance. The tablets were 
weighed individually and compared with average weight. The 
requirements are met if the weights of not more than 2 tablets differ 
by more than the percentage listed in the table 7 and no tablets 
differ in weight by more than double that percentage.  
Thickness 
Thickness and diameter of formulation trials were measured using a 
digital hardness tester. 10 tablets of each trial formulation were 
taken and measured individually at frequent intervals. 
The thickness of formulations LSC-N1 to LSC-N8 was found to be in 
the range of 3.98 mm to 4.14 mm and the formulations LSC-F1 to 
LSC-F8 was found to be in the range of 4.46 mm to 4.57 mm. 
 
Table 7: Acceptance criteria for weight variation 
Average weight of tablet (mg) %±deviation allowed 
130 or less  10 
More than 130 & less than 324  7.5 
324 and above  5 
As per the USP limits the % deviation for an uncoated tablet of weight for 324 mg and above is±5 %. The percentage deviation of all tablet 
formulations was found within±5 % and hence all the liquisolid batches pass the weight variation test as per USP. 
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Hardness 
10 tablets from each batch were selected and hardness was 
measured using hardness tester to find the average tablet hardness 
or crushing strength. 
The hardness of the formulations LSC-N1 to LSC-N8 & LSC-F1 to 
LSC-F8 was found to be in the range of 4.8–5.08 and 4.04–4.97 
kg/cm2 respectively. The acceptable hardness should be equal to or 
more than 4.5 kg/cm2
The tablet disintegration time ranges from 150 to 226 seconds for 
LSC-N1 to LSC-N8 formulations and 130 to 224 s for LSC-F1 to LSC-
F8. The disintegration time was found to within the acceptable 
range. It is clearly evident that as the concentration of disintegrant 
increased, the disintegration time decreased. 
.  
Disintegration time 
Disintegration test, measured using USP tablet disintegration test 
apparatus (TGR56, Electro lab, India) using 900 ml of distilled water at 
room temperature (37±2 ⁰C). For a drug to be absorbed from a solid 
dosage form after oral administration, it must first be in solution, and 
the condition is break up of the tablet, a process called disintegration. 
The disintegration test is a measure of the time required under a given 
set of conditions for a group of tablets to disintegrate into particles 
which will pass through a 10 mesh screen. Generally the test is useful 
as a quality assurance tool for dosage forms.  
The USP device to test disintegration uses 6 glass tubes that are 3 
inches long; open at the top and 10 mesh screens at the bottom end. 
To test, 1 tablet is placed in each tube and the basket rack is positioned 
in a 900 ml beaker of water, simulated gastric fluid or simulated 
intestinal fluid at 37±2 °C such that the tablet remains 2.5 cm below 
the surface of liquid on their upward movement and not closer than 
2.5 cm from the bottom of the beaker in their downward movement. 
Move the basket containing the tablets up and down through a 
distance of 5-6 cm at a frequency of 28-32 cycles per minute. Floating 
of the tablet can be prevented by placing perforated plastic discs on 
each tablet. According to the test, the tablet must disintegrate, and all 
particles must pass through the 10 mesh screen in the time specified. If 
any residue remains, it must have a soft mass. If 1 or 2 tablets fail to 
disintegrate, the test is repeated using 12 tablets. 
Content uniformity 
Ten tablets from each formulation were powdered. The powdered 
sample equivalent to 100 mg of drug was transferred to a 100 ml 
volumetric flask containing 100 ml of methanol. The contents were 
shaken up to 30 min. The solution was further diluted with 1% SLS 
solution. The drug content was determined by measuring the 
absorbance at 247 nm. 
Drug content for formulations LSC-N1 to LSC-N8 was found to be in 
the range of 98.16-99.12%. In the case of LSC-F1 to LSC-F8 was 
found to be in the range of 98.12-99.23%. 
In-vitro dissolution studies 
All the prepared liquisolid compacts of efavirenz using neusilin 
(LSC-N1 to LSC-N8) and fujicalin (LSC-F1 to LSC-F8) were subjected 
for in-vitro drug release studies. The dissolution studies were 
conducted simultaneously for the pure drug (100 mg in capsule) and 
for the physical mixture (tablet) in 0.1 N hydrochloric acid solution 
using Type-II apparatus. All the studies were conducted in triplicate 
at 50 rpm and at 37±0.5 °C.  
All the liquisolid compacts showed that the drug release was more 
than 80 % in 30 min for all the LSC formulations LSC-N1 to LSC-N8 
prepared with Neusilin. Further, the formulation LSC-N8 showed 
almost complete release in 45 min. The drug release from the 
physical mixture and pure drug were limited to the extent of 31.5 
and 28.0 % respectively in 35 min. Thus, the in-vitro dissolution 
studies indicated the importance of liquisolid compacts to enhance 
the solubility and dissolution rates. 
The release data obtained for the best formulations (LSC-N8 and 
LSC-F8) along with pure drug and physical mixture were 
tabulated as a ready reference in table 8 and the data was 
plotted in the fig. 5. 
 
Table 8: In-vitro dissolution data obtained for LSC-N8, pure drug and physical mixture 
Time (min) Percentage cumulative drug release* (AM±SD) 
LSC-N8 Physical mixture Pure drug 
0 0.00±0.00 0.00±0.00 0.00±0.00 
5 54.60±0.03 9.0±0.05 2.5±0.04 
10 62.01±0.08 15.0±0.09 7.8±0.11 
15 72.70±0.45 20.0±0.24 15.0±0.23 
20 80.02±0.06 22.0±0.09 19.0±0.98 
25 88.90±0.66 28.0±0.08 22.00.08 
30 94.08±0.32 31.5±0.32 25.0±0.15 
35 99.98±0.09 34.6±0.06 28.0±0.07 
 
 
Fig. 5: Comparative in-vitro dissolution profile of the optimized 
formulation LSC-N8, pure drug and physical mixture 
CONCLUSION 
Efavirenz being a poorly water soluble drug can be made to provide 
a better treatment if the drug is released effectively and this is 
achieved by formulating the drug as liquisolid compacts. A 23
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